A Novel, Broad-Spectrum Inhibitor of Enterovirus Replication That Targets Host Cell Factor Phosphatidylinositol 4-Kinase IIIβ

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 10, 2013, Pages 4971-4981

  Van Der Schaar, Hilde M ^a   Leyssen, Pieter ^d   Thibaut, Hendrik J ^d   De Palma, Armando ^d   Van Der Linden, Lonneke ^b,c,d   Lanke, Kjerstin H W ^b,c   Lacroix, Céline ^d   Verbeken, Erik ^e   Conrath, Katja ^f   MacLeod, Angus M ^g   Mitchell, Dale R ^g   Palmer, Nicholas J ^g   Van De Poël, Hervé ^g   Andrews, Martin ^f   Neyts, Johan ^d   Van Kuppeveld, Frank J M ^a,b,c  

^a UTRECHT UNIVERSITY   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^e DEPARTMENT OF IMAGING AND PATHOLOGY   (Belgium)

^f GALAPAGOS NV   (Belgium)

^g BioFocus DPI   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1,2 FLUORO 4 (2 METHYL 8 (3 (METHYLSULFONYL)BENZYLAMINO)IMIDAZO[1,2 ALPHA]PYRAZIN 3 YL)PHENOL; 1,3 (3 FLUORO 4 METHOXYPHENYL) 2 METHYL N (PYRIDIN 4 YLMETHYL)IMIDAZO[1,2 ALPHA]PYRAZIN 8 AMINE; ADENOSINE TRIPHOSPHATE; ANTIVIRUS AGENT; HOST FACTOR; PHOSPHATIDYLINOSITOL 4 PHOSPHATE 3 KINASE; PHOSPHATIDYLINOSITOL 4 PHOSPHATE 3 KINASE BETA; UNCLASSIFIED DRUG; VIRUS RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; COXSACKIE VIRUS; DISTRIBUTION VOLUME; DRUG ANALYSIS; DRUG CLEARANCE; DRUG INHIBITION; DRUG STRUCTURE; DRUG TOLERABILITY; ENTEROVIRUS; ENZYME ASSAY; HOST CELL; IN VITRO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; MUTANT; NONHUMAN; PANCREATITIS; PRIORITY JOURNAL; RHINOVIRUS; SUBSTITUTION REACTION; TIME TO MAXIMUM PLASMA CONCENTRATION; VIRUS ISOLATION; VIRUS REPLICATION;

1-PHOSPHATIDYLINOSITOL 4-KINASE; ANIMALS; ANTIVIRAL AGENTS; ENTEROVIRUS; ENZYME ACTIVATION; FLUORESCENT ANTIBODY TECHNIQUE; HELA CELLS; HUMANS; MALE; MICE; MOLECULAR STRUCTURE; PANCREATITIS; VIRUS REPLICATION;

EID: 84884272857     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01175-13     Document Type: Article

References (58)

1. Palacios G, Oberste MS. 2005. Enteroviruses as agents of emerging infectious diseases. J. Neurovirol. 11:424-433.
2. Ooi MH, Wong SC, Lewthwaite P, Cardosa MJ, Solomon T. 2010. Clinical features, diagnosis, and management of enterovirus. Lancet Neurol. 9:1097-1105.
3. Sawyer MH. 2002. Enterovirus infections: diagnosis and treatment. Semin. Pediatr. Infect. Dis. 13:40-47.
4. Whitton JL, Cornell CT, Feuer R. 2005. Host and virus determinants of picornavirus pathogenesis and tropism. Nat. Rev. Microbiol. 3:765-776.
5. Yeung W-CG, Rawlinson WD, Craig ME. 2011. Enterovirus infection and type 1 diabetes mellitus: systematic review and meta-analysis of observational molecular studies. BMJ 342:d35. doi:10.1136/bmj.d35.
6. Kaida A, Kubo H, Sekiguchi J, Kohdera U, Togawa M, Shiomi M, Nishigaki T, Iritani N. 2011. Enterovirus 68 in children with acute respiratory tract infections, Osaka, Japan. Emerg. Infect. Dis. 17:1494-1497.
7. Lévêque N, Huguet P, Norder H, Chomel J-J. 2010. Enteroviruses responsible for acute hemorrhagic conjunctivitis. Med. Mal. Infect. 40: 212-218. (In French.)
8. Rotbart HA. 2000. Antiviral therapy for enteroviruses and rhinoviruses. Antivir. Chem. Chemother. 11:261-271.
9. Turner RB. 1998. The common cold. Pediatr. Ann. 27:790-795.
10. Liang Z, Mao Q, Gao F, Wang J. 2013. Progress on the research and development of human enterovirus 71 (EV71) vaccines. Front. Med. 7:111-121.
11. Zhu F-C, Liang Z-L, Li X-L, Ge H-M, Meng F-Y, Mao Q-Y, Zhang Y-T, Hu Y-M, Zhang Z-Y, Li J-X, Gao F, Chen Q-H, Zhu Q-Y, Chu K, Wu X, Yao X, Guo H-J, Chen X-Q, Liu P, Dong Y-Y, Li F-X, Shen X-L, Wang J-Z. 2013. Immunogenicity and safety of an enterovirus 71 vaccine in healthy Chinese children and infants: a randomised, double-blind, placebo-controlled phase 2 clinical trial. Lancet 381:1037-1045.
12. Tuthill TJ, Groppelli E, Hogle JM, Rowlands DJ. 2010. Picornaviruses. Curr. Top. Microbiol. Immunol. 343:43-89.
13. Bedard KM, Semler BL. 2004. Regulation of picornavirus gene expression. Microbes Infect. 6:702-713.
14. Bienz K, Egger D, Pasamontes L. 1987. Association of polioviral proteins of the P2 genomic region with the viral replication complex and virusinduced membrane synthesis as visualized by electron microscopic immunocytochemistry and autoradiography. Virology 160:220-226.
15. Limpens RWAL, Kumar D, Transformation T, Structures ER, Study T, Compartments D, This S, Feeds RSS, Journal ASM. 2011. The transformation of enterovirus replication structures: a three-dimensional study of single-and double-membrane compartments. mBio 2(5):e00166 -11. doi: 10.1128/mBio.00166-11.
16. Belov GA, Nair V, Hansen BT, Hoyt FH, Fischer ER, Ehrenfeld E. 2012. Complex dynamic development of poliovirus membranous replication complexes. J. Virol. 86:302-312.
17. Belov GA, Feng Q, Nikovics K, Jackson CL, Ehrenfeld E. 2008. A critical role of a cellular membrane traffic protein in poliovirus RNA replication. PLoS Pathog. 4(11):e1000216. doi:10.1371/journal.ppat.1000216.
18. Lanke KHW, van der Schaar HM, Belov GA, Feng Q, Duijsings D, Jackson CL, Ehrenfeld E, van Kuppeveld FJM. 2009. GBF1, a guanine nucleotide exchange factor for Arf, is crucial for coxsackievirus B3 RNA replication. J. Virol. 83:11940-11949.
19. Wessels E, Duijsings D, Niu T-K, Neumann S, Oorschot VM, de Lange F, Lanke KHW, Klumperman J, Henke A, Jackson CL, Melchers WJG, van Kuppeveld FJM. 2006. A viral protein that blocks Arf1-mediated COP-I assembly by inhibiting the guanine nucleotide exchange factor GBF1. Dev. Cell 11:191-201.
20. Van der Schaar HM, van der Linden L, Lanke KHW, Strating JRPM, Pürstinger G, de Vries E, de Haan C a M, Neyts J, van Kuppeveld FJM. 2012. Coxsackievirus mutants that can bypass host factor PI4KIII and the need for high levels of PI4P lipids for replication. Cell Res. 22:1-17.
21. Hsu N-Y, Ilnytska O, Belov G, Santiana M, Chen Y-H, Takvorian PM, Pau C, van der Schaar H, Kaushik-Basu N, Balla T, Cameron CE, Ehrenfeld E, van Kuppeveld FJM, Altan-Bonnet N. 2010. Viral reorganization of the secretory pathway generates distinct organelles for RNA replication. Cell 141:799-811.
22. Arita M, Kojima H, Nagano T, Okabe T, Wakita T, Shimizu H. 2011. Phosphatidylinositol 4-kinase III beta is a target of enviroxime-like compounds for antipoliovirus activity. J. Virol. 85:2364-2372.
23. Thibaut HJ, De Palma AM, Neyts J. 2012. Combating enterovirus replication: state-of-the-art on antiviral research. Biochem. Pharmacol. 83: 185-192.
24. Norder H, De Palma AM, Selisko B, Costenaro L, Papageorgiou N, Arnan C, Coutard B, Lantez V, De Lamballerie X, Baronti C, Solà M, Tan J, Neyts J, Canard B, Coll M, Gorbalenya AE, Hilgenfeld R. 2011. Picornavirus non-structural proteins as targets for new anti-virals with broad activity. Antiviral Res. 89:204-218.
25. Gallay PA, Lin K. 2013. Profile of alisporivir and its potential in the treatment of hepatitis C. Drug Des. Dev. Ther. 7:105-115.
26. Coelmont L, Hanoulle X, Chatterji U, Berger C, Snoeck J, Bobardt M, Lim P, Vliegen I, Paeshuyse J, Vuagniaux G, Vandamme A-M, Bartenschlager R, Gallay P, Lippens G, Neyts J. 2010. DEB025 (Alisporivir) inhibits hepatitisCvirus replication by preventing a cyclophilinAinduced cis-trans isomerisation in domain II of NS5A. PLoS One 5(10):e13687. doi:10.1371/journal.pone.0013687.
27. Macleod AM, Mitchell DR, Palmer NJ, Van de Poel H, Conrath K, Andrews M, Leyssen P, Neyts J. 2013. Identification of a series of compounds with potent antiviral activity for the treatment of enterovirus infections. ACS Med. Chem. Lett. 4:585-589.
28. De Palma AM, Thibaut HJ, van der Linden L, Lanke K, Heggermont W, Ireland S, Andrews R, Arimilli M, Al-Tel TH, De Clercq E, van Kuppeveld F, Neyts J. 2009. Mutations in the nonstructural protein 3A confer resistance to the novel enterovirus replication inhibitor TTP-8307. Antimicrob. Agents Chemother. 53:1850-1857.
29. Wessels E, Duijsings D, Notebaart RA, Melchers WJG, van Kuppeveld FJM. 2005. A proline-rich region in the coxsackievirus 3A protein is required for the protein to inhibit endoplasmic reticulum-to-Golgi transport. J. Virol. 79:5163-5173.
30. De Palma AM, Heggermont W, Leyssen P, Pürstinger G, Wimmer E, De Clercq E, Rao A, Monforte A-M, Chimirri A, Neyts J. 2007. Antienterovirus activity and structure-activity relationship of a series of 2,6-dihalophenyl- substituted 1H,3H-thiazolo[3,4-a]benzimidazoles. Biochem. Biophys. Res. Commun. 353:628-632.
31. Balla A, Tuymetova G, Toth B, Szentpetery Z, Zhao X, Knight ZA, Shokat K, Steinbach PJ, Balla T. 2008. Design of drug-resistant alleles of type-III phosphatidylinositol 4-kinases using mutagenesis and molecular modeling. Biochemistry 47:1599-1607.
32. Downing GJ, Kim S, Nakanishi S, Catt KJ, Balla T. 1996. Characterization of a soluble adrenal phosphatidylinositol 4-kinase reveals wortmannin sensitivity of type III phosphatidylinositol kinases. Biochemistry 35: 3587-3594.
33. Godi A, Di Campli A, Konstantakopoulos A, Di Tullio G, Alessi DR, Kular GS, Daniele T, Marra P, Lucocq JM, De Matteis MA. 2004. FAPPs control Golgi-to-cell-surface membrane traffic by binding to ARF and PtdIns(4)P. Nat. Cell Biol. 6:393-404.
34. He J, Scott JL, Heroux A, Roy S, Lenoir M, Overduin M, Stahelin RV, Kutateladze TG. 2011. Molecular basis of phosphatidylinositol 4-phosphate and ARF1 GTPase recognition by the FAPP1 pleckstrin homology (PH) domain. J. Biol. Chem. 286:18650-18657.
35. Tóth B, Balla A, Ma H, Knight ZA, Shokat KM, Balla T. 2006. Phosphatidylinositol 4-kinase III regulates the transport of ceramide between the endoplasmic reticulum and Golgi. J. Biol. Chem. 281:36369-36377.
36. Balla A, Tuymetova G, Tsiomenko A, Balla T. 2005. A plasma membrane pool of phosphatidylinositol 4-phosphate is generated by phosphatidylinositol 4-kinase type-III alpha: studies with the PH domains of the oxysterol binding protein and FAPP1. Mol. Biol. Cell 16:1282-1295.
37. Garuti L, Roberti M, Bottegoni G. 2010. Non-ATP competitive protein kinase inhibitors. Curr. Med. Chem. 17:2804-2821.
38. Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, McLauchlan H, Klevernic I, Arthur JSC, Alessi DR, Cohen P. 2007. The selectivity of protein kinase inhibitors: a further update. Biochem. J. 408:297-315.
39. De Palma AM, Verbeken E, Van Aelst I, Van den Steen PE, Opdenakker G, Neyts J. 2008. Increased gelatinase B/matrix metalloproteinase 9 (MMP-9) activity in a murine model of acute coxsackievirus B4-induced pancreatitis. Virology 382:20-27.
40. Sasaki J, Ishikawa K, Arita M, Taniguchi K. 2012. ACBD3-mediated recruitment of PI4KB to picornavirus RNA replication sites. EMBO J. 31:754-766.
41. Berger KL, Cooper JD, Heaton NS, Yoon R, Oakland TE, Jordan TX, Mateu G, Grakoui A, Randall G. 2009. Roles for endocytic trafficking and phosphatidylinositol 4-kinase III alpha in hepatitis C virus replication. Proc. Nat. Acad. Sci. U. S. A. 106:7577-7582.
42. Borawski J, Troke P, Puyang X, Gibaja V, Zhao S, Mickanin C, Leighton-Davies J, Wilson CJ, Myer V, Cornellataracido I, Baryza J, Tallarico J, Joberty G, Bantscheff M, Schirle M, Bouwmeester T, Mathy JE, Lin K, Compton T, Labow M, Wiedmann B, Gaither LA. 2009. Class III phosphatidylinositol 4-kinase alpha and beta are novel host factor regulators of hepatitis C virus replication. J. Virol. 83:10058-10074.
43. Reiss S, Rebhan I, Backes P, Romero-Brey I, Erfle H, Matula P, Kaderali L, Poenisch M, Blankenburg H, Hiet M-S, Longerich T, Diehl S, Ramirez F, Balla T, Rohr K, Kaul A, Bühler S, Pepperkok R, Lengauer T, Albrecht M, Eils R, Schirmacher P, Lohmann V, Bartenschlager R. 2011. Recruitment and activation of a lipid kinase by hepatitis C virus NS5A is essential for integrity of the membranous replication compartment. Cell Host Microbe 9:32-45.
44. Tai AW, Benita Y, Peng LF, Kim S-S, Sakamoto N, Xavier RJ, Chung RT. 2009. A functional genomic screen identifies cellular cofactors of hepatitis C virus replication. Cell Host Microbe 5:298-307.
45. Trotard M, Lepère-Douard C, Régeard M, Piquet-Pellorce C, Lavillette D, Cosset F-L, Gripon P, Le Seyec J. 2009. Kinases required in hepatitis C virus entry and replication highlighted by small interference RNA screening. FASEB J. 23:3780-3789.
46. Vaillancourt FH, Pilote L, Cartier M, Lippens J, Liuzzi M, Bethell RC, Cordingley MG, Kukolj G. 2009. Identification of a lipid kinase as a host factor involved in hepatitis C virus RNA replication. Virology 387:5-10.
47. Tai AW, Salloum S. 2011. The role of the phosphatidylinositol 4-kinase PI4KA in hepatitis C virus-induced host membrane rearrangement. PLoS One 6(10):e26300. doi:10.1371/journal.pone.0026300.
48. Yang N, Ma P, Lang J, Zhang Y, Deng J, Ju X, Zhang G, Jiang C. 2012. Phosphatidylinositol 4-kinase III is required for severe acute respiratory syndrome coronavirus spike-mediated cell entry. J. Biol. Chem. 287:8457-8467.
49. Vaillancourt FH, Brault M, Pilote L, Uyttersprot N, Gaillard ET, Stoltz JH, Knight BL, Pantages L, McFarland M, Breitfelder S, Chiu TT, Mahrouche L, Faucher A-M, Cartier M, Cordingley MG, Bethell RC, Jiang H, White PW, Kukolj G. 2012. Evaluation of phosphatidylinositol-4-kinase III as a hepatitis C virus drug target. J. Virol. 86:11595-11607.
50. Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, Loewith R, Stokoe D, Balla A, Toth B, Balla T, Weiss WA, Williams RL, Shokat KM. 2006. A pharmacological map of the PI3-K family defines a role for p110 in insulin signaling. Cell 125:733-747.
51. Arita M, Wakita T, Shimizu H. 2008. Characterization of pharmacologically active compounds that inhibit poliovirus and enterovirus 71 infectivity. J. Gen. Virol. 89:2518-2530.
52. Phillpotts RJ, Jones RW, Delong DC, Reed SE, Wallace J, Tyrrell DA. 1981. The activity of enviroxime against rhinovirus infection in man. Lancet i:1342-1344.
53. Phillpotts RJ, Wallace J, Tyrrell DA, Tagart VB. 1983. Therapeutic activity of enviroxime against rhinovirus infection in volunteers. Antimicrob. Agents Chemother. 23:671-675.
54. Lamarche MJ, Borawski J, Bose A, Capacci-Daniel C, Colvin R, Dennehy M, Ding J, Dobler M, Drumm J, Gaither LA, Gao J, Jiang X, Lin K, McKeever U, Puyang X, Raman P, Thohan S, Tommasi R, Wagner K, Xiong X, Zabawa T, Zhu S, Wiedmann B. 2012. Anti-hepatitis C virus activity and toxicity of type III phosphatidylinositol-4-kinase beta inhibitors. Antimicrob. Agents Chemother. 56:5149-5156.
55. Spickler C, Lippens J, Laberge M-K, Desmeules S, Bellavance E, Garneau M, Guo T, Hucke O, Leyssen P, Neyts J, Vaillancourt FH, Décor A, O'Meara J, Franti M, Gauthier A. 2013. Phosphatidylinositol 4-kinase III beta is essential for the replication of human rhinovirus and its inhibition causes a lethal phenotype in vivo. Antimicrob. Agents Chemother. 57:3358-3368.
56. Susser S, Vermehren J, Forestier N, Welker MW, Grigorian N, Füller C, Perner D, Zeuzem S, Sarrazin C. 2011. Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir. J. Clin. Virol. 52:321-327.
57. Susser S, Welsch C, Wang Y, Zettler M, Domingues FS, Karey U, Hughes E, Ralston R, Tong X, Herrmann E, Zeuzem S, Sarrazin C. 2009. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatology 50:1709 -1718.
58. Geller R, Vignuzzi M, Andino R, Frydman J. 2007. Evolutionary constraints on chaperone-mediated folding provide an antiviral approach refractory to development of drug resistance. Genes Dev. 21: 195-205.